Drug intelligence / Profile preview

AT720

Development stage: Preclinical
Lead developer: Astellas Gene Therapies
Modality: Gene Therapies

Overview

**AT720** is a novel AAV-based gene therapy developed by Audentes Therapeutics for the treatment of a large neuromuscular disease. It employs adeno-associated virus (AAV) vectors to deliver genetic material aimed at addressing the underlying genetic defects in neuromuscular disorders, potentially offering a one-time treatment option. As of the latest available data, it remains in early preclinical development stages.

Beyond the preview

Go deeper on AT720.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT720.

Explore the full profile